PDS Biotechnology Corp financial data

Symbol
PDSB on Nasdaq
Industry
Pharmaceutical Preparations
Location
303 A College Road East, Princeton, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Edge Therapeutics, Inc. (to 3/18/2019)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 542 % -54%
Debt-to-equity 107 % +112%
Return On Equity -146 % -59.3%
Return On Assets -70.4 % -15.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.7 M shares +19.4%
Common Stock, Shares, Outstanding 36.7 M shares +19.4%
Entity Public Float 148 M USD +50.8%
Common Stock, Value, Issued 12.1 K USD +19.4%
Weighted Average Number of Shares Outstanding, Basic 34.8 M shares +14.4%
Weighted Average Number of Shares Outstanding, Diluted 34.8 M shares +14.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 28.6 M USD -4.95%
General and Administrative Expense 15.1 M USD +20.8%
Operating Income (Loss) -43.7 M USD -2.59%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.3 M USD -5.46%
Income Tax Expense (Benefit) -1.41 M USD -17.3%
Net Income (Loss) Attributable to Parent -43.9 M USD -4.39%
Earnings Per Share, Basic -1.37 USD/shares +4.2%
Earnings Per Share, Diluted -1.37 USD/shares +4.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 66.6 M USD +2.2%
Assets, Current 68.7 M USD +1.05%
Property, Plant and Equipment, Net 129 K USD -12.8%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 69 M USD +0.82%
Accounts Payable, Current 6 M USD +190%
Accrued Liabilities, Current 1.71 M USD -7.76%
Liabilities, Current 15.1 M USD +265%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 31.8 M USD +16%
Retained Earnings (Accumulated Deficit) -155 M USD -39.5%
Stockholders' Equity Attributable to Parent 37.2 M USD -9.33%
Liabilities and Equity 69 M USD +0.82%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.94 M USD +24.6%
Net Cash Provided by (Used in) Financing Activities 20 M USD +338%
Common Stock, Shares Authorized 75 M shares 0%
Common Stock, Shares, Issued 36.7 M shares +19.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 66.6 M USD +2.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.17 M USD +21.5%
Deferred Tax Assets, Valuation Allowance 56.6 M USD +33.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 56.7 M USD +33.3%
Operating Lease, Liability 59.7 K USD -84.9%
Depreciation 4.74 K USD +50.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -43.9 M USD -4.39%
Lessee, Operating Lease, Liability, to be Paid 60.3 K USD -85.6%
Property, Plant and Equipment, Gross 267 K USD +131%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 683 USD -97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 192 M USD +26.3%
Deferred Tax Assets, Net of Valuation Allowance 56.8 K USD -61.7%
Share-based Payment Arrangement, Expense 7.61 M USD +46.5%
Interest Expense 4.41 M USD +93.3%